TP-251

TP-251 is a bacteriophage-based therapeutic candidate currently in early-stage development by TechnoPhage, a biotechnology company specializing in phage-based solutions for antimicrobial resistance. While the specific bacterial target and primary clinical indication for TP-251 remain undisclosed by the sponsor, the asset is part of a broader pipeline of biological products designed to address infectious diseases. The drug leverages TechnoPhage's proprietary platform to identify and develop lytic bacteriophages that can selectively target and eliminate pathogenic bacteria, potentially serving as an alternative or adjunct to traditional antibiotic therapies.